Longbow Finance SA Purchases 24,044 Shares of Gilead Sciences, Inc. $GILD

Longbow Finance SA raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 35.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 92,811 shares of the biopharmaceutical company’s stock after acquiring an additional 24,044 shares during the period. Longbow Finance SA’s holdings in Gilead Sciences were worth $10,302,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its holdings in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Gilead Sciences by 2.6% in the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $2,150,268,000. Invesco Ltd. raised its position in Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares during the last quarter. Finally, Amundi lifted its holdings in Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after buying an additional 1,614,355 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the sale, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. This represents a 2.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 319,391 shares of company stock valued at $44,141,101 over the last three months. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several research reports. Rothschild & Co Redburn lifted their target price on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Truist Financial raised their price target on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. Argus upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, BMO Capital Markets raised their target price on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, January 26th. Twenty-three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $152.42.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat consensus — revenue and EPS topped estimates, driven by HIV and liver‑disease portfolio strength and early traction for new products; this underpins analyst bullishness and longer‑term revenue visibility. GILD’s Q4 Earnings Beat
• Positive Sentiment: Big wave of analyst price‑target increases and buy/outperform notes (examples: Morgan Stanley $171, Scotiabank $177, Needham/Wolfe $170, Wells Fargo & JPMorgan mid‑$160s) — brokers cite HIV momentum, margin expansion and product pipeline (Yeztugo, Yescarta) as reasons to raise targets. Analyst Coverage Summary
• Positive Sentiment: Dividend increase announced — quarterly dividend up to $0.82 (3.8% raise), supporting income investor appeal and signaling management confidence in cash flow.
• Neutral Sentiment: Earnings call / transcripts published (multiple outlets) — useful for detail on guidance assumptions, product rollouts and cost/margin outlook but neutral until investors parse management commentary. Earnings Call Transcript
• Neutral Sentiment: Yescarta label expansion and new product commentary appear in coverage — potential medium‑term upside if uptake meets expectations; currently a pipeline/progression read‑through. Yescarta & Dividend Coverage
• Neutral Sentiment: Short‑interest notes in data feeds show anomalous 0 shares / NaN changes — not meaningful evidence of a short squeeze or new bearish positioning based on available figures.
• Negative Sentiment: FY‑2026 guidance came in below some Street expectations — management’s outlook tempered the post‑earnings rally and is the principal reason for the intraday/extended‑session pullback despite the beat. Guidance / Shares Dip
• Negative Sentiment: At least one broker adjustment (Royal Bank of Canada) shows a lower relative price target in published feeds despite a PT raise vs. prior internal note — highlights disagreement among analysts on near‑term valuation and reinforces guidance‑driven uncertainty. RBC / Ticker Report

Gilead Sciences Trading Down 2.6%

NASDAQ:GILD opened at $151.81 on Friday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The business has a 50 day moving average price of $129.59 and a two-hundred day moving average price of $121.98. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The company has a market cap of $188.35 billion, a P/E ratio of 22.42, a price-to-earnings-growth ratio of 0.81 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The business’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is presently 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.